Topics
Glioblastoma | Treatment | Targeted therapy | Bevacizumab | Patient selection
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Bevacizumab > Patient selection
Bobholz SA, Hoefs A, Hamburger J,
Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D,
Krucoff M, Banerjee A, LaViolette PS.
Radio-pathomic
maps of glioblastoma identify phenotypes of non-enhancing tumor
infiltration associated with bevacizumab treatment response.
Res
Sq [Preprint].
2024 Jan 8:rs.3.rs-3832221. doi:
10.21203/rs.3.rs-3832221/v1. PMID:
38260400. Observational study. ˍ
*Hiller-Vallina S, Mondejar-Ruescas L, Caamaño-Moreno M,
Cómitre-Mariano B, Alcivar-López D, Sepulveda JM,
Hernández-Laín A, Pérez-Núñez
Á, Segura-Collar B, Gargini R.
Sexual-biased
necroinflammation is revealed as a predictor of bevacizumab
benefit in Glioblastoma.
Neuro
Oncol. 2024 Feb 27:noae033. doi:
10.1093/neuonc/noae033. PMID:
38411438. Observational study. ˍ